v3.25.1
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (Unaudited) - USD ($)
$ in Thousands
Total
Preferred Stock [Member]
Convertible Preferred Stock [Member]
Common Stock [Member]
Class A Common Stock [Member]
Common Stock [Member]
Class B Common Stock [Member]
Additional Paid-in Capital [Member]
Accumulated Deficit [Member]
Beginning Balance at Dec. 31, 2023 $ (101,842) $ 129,825     $ 209 $ (102,051)
Beginning Balance (in shares) at Dec. 31, 2023     313,747      
Convertible Preferred Stock Beginning Balance (in shares) at Dec. 31, 2023   6,840,620        
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Issuance of Class A Common Stock from the exercise of stock options 10       10  
Issuance of Class A Common Stock from the exercise of stock options (in shares)     1,002      
Share-based compensation expense 107       107  
Net loss (9,536)         (9,536)
Ending Balance at Mar. 31, 2024 (111,261) $ 129,825     326 (111,587)
Ending Balance (in shares) at Mar. 31, 2024     314,749      
Convertible Preferred Stock Ending Balance (in shares) at Mar. 31, 2024   6,840,620        
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Issuance of Class A Common Stock from the exercise of stock options 10       10  
Issuance of Class A Common Stock from the exercise of stock options (in shares)     1,130      
Share-based compensation expense 1,813       1,813  
Net loss (14,139)         (14,139)
Ending Balance at Jun. 30, 2024 (123,577) $ 129,825     2,149 (125,726)
Ending Balance (in shares) at Jun. 30, 2024     315,879      
Convertible Preferred Stock Ending Balance (in shares) at Jun. 30, 2024   6,840,620        
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Issuance of Class A Common Stock from the exercise of stock options 6       6  
Issuance of Class A Common Stock from the exercise of stock options (in shares)     344      
Share-based compensation expense 77       77  
Net loss (11,556)         (11,556)
Ending Balance at Sep. 30, 2024 (135,050) $ 129,825     2,232 (137,282)
Ending Balance (in shares) at Sep. 30, 2024     316,223      
Convertible Preferred Stock Ending Balance (in shares) at Sep. 30, 2024   6,840,620        
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Conversion of Convertible Preferred Stock for Class A and B Common Stock in connection with the Merger 129,825 $ (129,825) $ 1   129,824  
Conversion of Convertible Preferred Stock for Class A and B Common Stock in connection with the Merger (in shares)   (6,840,620) 6,154,093 686,527    
Issuance of Class A Common Stock in the Concurrent Financing, less issuance costs (in shares) 54,428       54,428  
Issuance of Class A Common Stock in the Concurrent Financing, less issuance costs     2,571,736      
Issuance of common stock to former stockholders of Reneo Pharmaceuticals, Inc. in connection with the closing of the reverse recapitalization 65,499       65,499  
Issuance of common stock to former stockholders of Reneo Pharmaceuticals, Inc. in connection with the closing of the reverse recapitalization (in shares)     3,343,604      
Reverse recapitalization transaction costs of OnKure (2,085)       (2,085)  
Issuance of Class A Common Stock for the conversion of Convertible Promissory Notes 6,120       6,120  
Issuance of Class A Common Stock for the conversion of Convertible Promissory Notes (in shares)     267,269      
Issuance of Class A common stock for the settlement of restricted stock units, net of shares withheld to cover taxes (in shares)     7,700      
Adjustment for fractional shares in the reverse recapitalization     (35)      
Share-based compensation expense 2,533       2,533  
Net loss (17,442)         (17,442)
Ending Balance at Dec. 31, 2024 $ 103,828   $ 1   258,551 (154,724)
Ending Balance (in shares) at Dec. 31, 2024     12,660,590 686,527    
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Issuance of Class A Common Stock from the exercise of stock options (in shares) 0          
Vesting of restricted stock units, net     94,758      
Share-based compensation expense $ 2,745       2,745  
Net loss (15,925)         (15,925)
Ending Balance at Mar. 31, 2025 $ 90,648   $ 1   $ 261,296 $ (170,649)
Ending Balance (in shares) at Mar. 31, 2025     12,755,348 686,527